VEMURAFENIB FOR BRAF V600 MUTATED ADVANCED MELANOMA: RESULTS OF TREATMENT BEYOND PROGRESSION

被引：0
|
作者：
Haanen, J. B. A. G. [1 ]
Scholtens, A. [1 ]
Geukes, M. [1 ]
van Thienen, H. [1 ]
van Tinteren, H. [2 ]
机构：
[1] Netherlands Canc Inst, Amsterdam, Netherlands
[2] Netherlands Canc Inst, Dept Stat, Amsterdam, Netherlands
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu344.21
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1105P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Vemurafenib for BRAF V600 mutated advanced melanoma: Results of treatment beyond progression
    Scholtens, A.
    Foppen, M. H. Geukes
    Blank, C. U.
    van Thienen, J. V.
    van Tinteren, H.
    Haanen, J. B.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 (05) : 642 - 652
  • [2] Melanoma Effectiveness of Vemurafenib on BRAF V600 Mutations
    Voos, Dunja
    [J]. AKTUELLE DERMATOLOGIE, 2014, 40 (11) : 434 - 434
  • [3] Safety of vemurafenib in patients with BRAF V600 mutated metastatic melanoma: the Spanish experience
    Arance, A. M.
    Berrocal, A.
    Lopez-Martin, J. A.
    de la Cruz-Merino, L.
    Soriano, V.
    Martin Algarra, S.
    Alonso, L.
    Cerezuela, P.
    La Orden, B.
    Espinosa, E.
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2016, 18 (11): : 1147 - 1157
  • [4] Vemurafenib in non-melanoma V600 and non-V600 BRAF mutated cancers: Results of the AcSe basket trial
    Tomasini, P.
    Mazieres, J.
    Cropet, C.
    Troussard, X. G.
    Malka, D.
    Ray-Coquard, I. L.
    Leboulleux, S.
    Flechon, A.
    Arnulf, B.
    Cancel, M.
    Bieche, I.
    Collot, S.
    Taieb, S.
    Garcia, G.
    Mandache, A-M.
    Colignon, N.
    Gavrel, M.
    Jimenez, M.
    Hoog-Labouret, N.
    Blay, J-Y.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S470 - S471
  • [5] Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma
    Schmitt, Andreas M.
    Dumas, Lucy
    Larkin, James
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (01) : 17 - 25
  • [6] Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib
    Nowara, Elzbieta
    Huszno, Joanna
    Slomian, Grzegorz
    Nieckula, Jaroslaw
    [J]. POSTEPY DERMATOLOGII I ALERGOLOGII, 2016, 33 (01): : 52 - 56
  • [7] Vemurafenib (VM) in non-melanoma V600 and non-V600 BRAF mutated cancers: first results of the ACSE trial
    Blay, J-Y.
    Mazieres, J.
    Perol, D.
    Barlesi, F.
    Moro-Sibilot, D.
    Quere, G.
    Tredaniel, J.
    Troussard, X.
    Leboulleux, S.
    Malka, D.
    Flechon, A.
    Linassier, C.
    Ray-Coquard, I. L.
    Arnulf, B.
    Bieche, I.
    Ferretti, G.
    Nowak, F.
    Jimenez, M.
    Hoog-Labouret, N.
    Buzyn, A.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [8] Advances in Treatment for Patients Unresectable or Metastatic BRAF V600 Mutated Melanoma
    Ying, A. C. H.
    [J]. HONG KONG JOURNAL OF RADIOLOGY, 2013, 16 (04): : S34 - S38
  • [9] Treatment of patients with advanced melanoma harboring the BRAF V600 mutation
    Polowinczak-Przybylek, Joanna
    Potemski, Piotr
    [J]. ONCOLOGY IN CLINICAL PRACTICE, 2018, 14 (01): : 48 - 52
  • [10] Treatment beyond progression in advanced BRAF-mutated melanoma with vemurafenib and cobimetinib: Results from the BRIM7 trial
    Lewis, K.
    Ribas, A.
    Gonzalez, R.
    Hamid, O.
    Daud, A.
    Puzanov, I.
    Hsu, J.
    Choong, N.
    Koralek, D.
    McArthur, G.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S679 - S679
12345